Cripe Lab
Our primary mission and interest is the development of new therapies for cancer based on a platform of oncolytic viruses. Most of our work focuses on pediatric cancers. We have a cadre of tumor cell lines, human xenograft models, and mouse tumor models for our studies including those derived from a variety of rhabdomyosarcomas, Ewing sarcomas, osteosarcomas, and neuroblastomas. We seek to
- design novel recombinant adenoviruses and herpes simplex viruses whose binding and/or replication is targeted to cancer through peptide binding motifs, tissue-specific cis regulatory elements, or genetic mutations;
- investigate the mechanisms and tumor specificity of oncolytic viruses;
- dissect the role of innate and adaptive immunity in promoting or suppressing the antitumor effect of oncolytic viruses, and
- determine the barriers to effective systemic use of oncolytic viruses for the treatment of metastatic disease, thus facilitating the design and testing of methods to overcome those barriers.
Because our work is translational in nature, we also conduct pre-clinical efficacy, biodistribution, and toxicology studies of oncolytic viruses using Good Laboratory Practices (GLP) guidelines to support clinical trials of these agents.
Publications: Peer Reviewed
Note: The linked text below will take you to the journal's abstract of the article. Citations with a PDF icon next to them indicate that a PDF of the article is available on a Journal's site, and you may be able to access the PDF by clicking on the icon. Depending on the Journal's publishing policy, you may need a subscription to download the PDF.
Cripe TP, Thomson B, Boat TF, Williams DA. (2005) Promoting translational research in academic health centers: navigating the "roadmap". Acad Med 80:1012-8.
Currier MA, Adams LC, Mahller YY, Cripe TP. (2005) Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses. Cancer Gene Ther 12:407-16.
Parikh NS, Currier MA, Mahller YY, Adams LC, Di Pasquale B, Collins MH, Cripe TP. (2005) Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models. Pediatr Blood Cancer 44:469-78.
Halsted MJ, Perry LA, Cripe TP, Collins MH, Jakobovits R, Benton C, Halsted DG. Improving patient care: the use of digital teaching file to enhance clinicians' access to the intellectual capital of interdepartment conferences. American Journal of Roentgenology 182:307-9, 2004.
Dickens DS and Cripe TP. Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts. J Ped Hematology/Oncology 25:709-714, 2003.
Dickens DS, Kozielski R, Leavey PJ, Timmons C, Cripe TP. Cyclooxygenase-2 Expression Does Not Correlate With Outcome in Pediatric Sarcomas. J Ped Hematology/Oncology 25:282-285, 2003.
Arceci RJ and Cripe TP. Emerging Cancer-Targeted Therapies. Ped Clinics of N Amer 49:1339-1368, 2002.
Mehlman CT and Cripe TP. Osteosarcoma. eMedicine Journal [serial online] , 2002. Available at: http://www.emedicine.com/orthoped/topic531.htm.
Dickens DS, Kozielski R, Khan J, Forus A, and Cripe TP. Cyclooxygenase-2 Expression in Pediatric Sarcomas. Pediatric and Developmental Pathology 5:356-364, 2002.
Rice AM, Currier MA, Adams LC, Bharatan NS, Collins MH, Snyder JD, Khan J, and Cripe TP. Ewing sarcoma family of tumors express adenovirus receptors and are susceptible to adenovirus-mediated oncolysis. J Ped Hematology/Oncology, 24:527-533. 2002.
Bharatan NS, Currier MA, Cripe TP. Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses. J Ped Hematology/Oncology 24:447-453, 2002.
Cripe TP and Mackall CL. Exploiting genetic alterations to design novel therapies for cancer. Hematology/Oncology Clinics of North America 15:657-675, 2001.
Grawe G and Cripe TP. Myelodysplastic syndrome. eMedicine Journal [serial online] , 2001. Available at: http://www.emedicine.com/ped/topic1527.htm.
Cripe TP. Osteosarcoma. eMedicine Journal 2(7) [serial online] , 2001. Available at: http://www.emedicine.com/ped/topic1684.htm.
Cripe TP. Rhabdomyosarcoma. eMedicine Journal 2(7) [serial online] , 2001. Available at: http://www.emedicine.com/ped/topic2005.htm.
Cripe TP, Dunphy EJ, Holub AD, Saini A, Vasi N, Mahller Y, Collins MH, Snyder J, Krasnykh V, Curiel D, Wickham TJ, DeGregori J, Bergelson J, Currier M. Fiber Knob Modifications Overcome Low, Heterogeneous Expression of the Coxsackievirus-Adenovirus Receptor Which Limits Adenovirus Gene Transfer and Oncolysis for Human Rhabdomyosarcoma Cells. Cancer Research 61:2953-2960, 2001.
Contact Tim Cripe
Tim Cripe
Division of Hematology/Oncology
Children's Hospital Medical Center
3333 Burnet Ave.
Cincinnati, OH 45229
Phone 513-636-7241
Fax 513-636-3549
Email t.cripe@cchmc.org
